(Q30458310)

10 August 2017

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside (English)

1 reference

neurofibromatosis type II

10 August 2017

1 reference

7

Razelle Kurzrock

1 reference

10 August 2017

Vivek Subbiah

1

1 reference

10 August 2017

John Slopis

2

1 reference

10 August 2017

David S Hong

3

1 reference

10 August 2017

Leena M Ketonen

4

1 reference

10 August 2017

Jackson Hamilton

5

1 reference

10 August 2017

Ian E McCutcheon

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

27 December 2011

1 reference

Journal of Clinical Oncology

10 August 2017

1 reference

10 August 2017

30

1 reference

10 August 2017

5

1 reference

10 August 2017

e64-8

1 reference

Medical therapies for meningiomas

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

The neurofibromatoses. Part 2: NF2 and schwannomatosis.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Neurofibromatosis type 2 (NF2): a clinical and molecular review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Targeted drug therapy for meningiomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295556

26 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22203760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2011.38.2614

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22203760

1 reference